Pasireotide
An FDA-approved pan-somatostatin analog (SSTR1/2/3/5) used as first-line medical therapy for Cushing's disease and second-line for acromegaly.
What is Pasireotide?
Pasireotide is a synthetic cyclohexapeptide somatostatin analog developed by Novartis with a distinctive pan-receptor binding profile — it binds SSTR1, SSTR2, SSTR3, and SSTR5 with nanomolar affinity, unlike octreotide and lanreotide which are primarily SSTR2/SSTR5 agonists. High SSTR5 affinity makes it the preferred pituitary-directed drug for Cushing's disease, where corticotroph adenomas express SSTR5 densely. It received FDA approval as Signifor for Cushing's disease (2012) and Signifor LAR for acromegaly (2014, second-line after octreotide/lanreotide failure).
What Pasireotide Is Investigated For
Pasireotide is an FDA-approved pan-somatostatin analog whose clinical value comes from a receptor profile distinct from octreotide and lanreotide — high affinity at SSTR5 in addition to SSTR2, with meaningful SSTR1 and SSTR3 activity. That profile matters because corticotroph adenomas in Cushing's disease express SSTR5 far more densely than SSTR2, which is why pasireotide is the drug of choice for medical management of Cushing's after failed transsphenoidal surgery — a use case where octreotide and lanreotide work poorly. In acromegaly, pasireotide LAR is approved as second-line therapy after first-generation somatostatin analogs fail, with the head-to-head C2305 trial and the PAOLA trial both demonstrating superior biochemical control vs octreotide LAR in inadequately controlled patients. Pasireotide also has a phase II and phase III footprint in metastatic neuroendocrine tumors refractory to octreotide and a positive randomized trial in postoperative pancreatic fistula prevention after pancreatectomy. The headline safety differentiator is hyperglycemia: pasireotide causes new-onset diabetes or worsens existing diabetes in a majority of treated patients because its high SSTR5 affinity disproportionately suppresses insulin and the incretins GIP and GLP-1, with comparatively modest suppression of glucagon. This is a specialist-only drug used in endocrinology and surgical oncology, not a wellness peptide — the hyperglycemia signal, QT-prolongation caution, and monthly-injection logistics require managed care.
History & Discovery
Pasireotide was developed at Novartis (Sandoz's successor) in Basel during the late 1990s and early 2000s as part of an explicit program to overcome the narrow SSTR2/SSTR5 binding profile of octreotide. Native somatostatin-14 binds all five somatostatin receptor subtypes with roughly comparable affinity; octreotide, lanreotide, and the other first-generation analogs had traded that universal profile for plasma stability and protease resistance. The Novartis medicinal-chemistry program — led by Christian Bruns and colleagues — sought a metabolically stable small cyclic peptide that preserved broad SRIF-receptor binding. Their solution was a cyclohexapeptide template combining structural elements of SRIF-14 with D-amino-acid substitutions for protease resistance, designated SOM230. The foundational characterization paper (Bruns et al., European Journal of Endocrinology 2002) established that SOM230 bound SSTR1, SSTR2, SSTR3, and SSTR5 with nanomolar affinity — with 30-fold higher SSTR1 affinity and 40-fold higher SSTR5 affinity than octreotide, and only modestly lower SSTR2 affinity. This profile predicted activity in tumors expressing SSTR5 (particularly corticotroph adenomas in Cushing's disease) where octreotide performed poorly. The clinical program followed the receptor biology. Cushing's disease was the flagship indication because corticotroph adenomas densely express SSTR5 with limited SSTR2, and medical therapy options had been unsatisfactory — ketoconazole, metyrapone, and mitotane were off-label and problematic, with mifepristone only approved in February 2012 for hypercortisolism management. Colao and colleagues led the pivotal 12-month phase III trial published in the New England Journal of Medicine in March 2012, enrolling 162 patients randomized to subcutaneous pasireotide 600 or 900 mcg BID. Both doses produced ~50% median reduction in urinary free cortisol by month 2. The FDA approved Signifor for Cushing's disease in December 2012, following an EMA approval in April 2012. The acromegaly program used two pivotal trials. The C2305 head-to-head trial (Colao et al., JCEM 2014) randomized 358 medically-naive patients to pasireotide LAR 40 mg or octreotide LAR 20 mg, showing superior biochemical control with pasireotide (31.3% vs 19.2%). The PAOLA trial (Gadelha et al., Lancet Diabetes Endocrinology 2014) randomized patients inadequately controlled on first-generation analogs to pasireotide 40 mg, pasireotide 60 mg, or continued octreotide/lanreotide, with biochemical control rates of 15%, 20%, and 0% respectively. The FDA approved Signifor LAR for acromegaly in December 2014 as second-line therapy after octreotide or lanreotide failure. A parallel oncology program extended pasireotide into metastatic neuroendocrine tumors refractory to octreotide, and a positive single-center NEJM randomized trial (Allen et al., 2014) demonstrated reduced postoperative pancreatic fistula after pancreatectomy, prompting significant off-label surgical use. The defining side-effect story that emerged in parallel — hyperglycemia in a majority of treated patients, mechanistically tied to SSTR5-mediated insulin and incretin suppression — has shaped every subsequent dosing, monitoring, and patient-selection decision in the drug's clinical use.
How It Works
Pasireotide mimics somatostatin, the body's natural 'off switch' for many hormones, but with a wider receptor profile than older somatostatin drugs like octreotide. That wider profile lets it shut down cortisol-producing pituitary tumors (Cushing's disease) that octreotide cannot touch. The trade-off is that the same receptor affinity which makes it work also strongly suppresses insulin, which is why hyperglycemia and new-onset diabetes are the defining side effect.
Pasireotide is a synthetic cyclohexapeptide somatostatin analog engineered to retain broad somatotropin release-inhibiting-factor (SRIF) receptor binding rather than the narrow SSTR2/SSTR5 profile of octreotide. It binds with nanomolar affinity to SSTR1, SSTR2, SSTR3, and SSTR5, with particularly high affinity at SSTR5 — approximately 40-fold greater than octreotide — while SSTR2 affinity is modestly lower. Receptor activation inhibits adenylyl cyclase and reduces cAMP, suppressing hormone secretion from target cells. In Cushing's disease, the relevant target is SSTR5 on corticotroph pituitary adenomas, which densely express this subtype. SSTR5 activation suppresses ACTH release and lowers downstream cortisol. This mechanism is why pasireotide works in Cushing's disease where octreotide and lanreotide essentially do not — corticotroph adenomas under-express SSTR2. In acromegaly, both SSTR2 and SSTR5 are expressed on somatotroph adenomas, and pasireotide suppresses GH and IGF-1 through joint receptor engagement. In patients inadequately controlled on first-generation analogs, the added SSTR5 activity of pasireotide recruits additional biochemical control. The glycemic side-effect profile arises from the same receptor biology. SSTR5 is highly expressed on pancreatic beta cells and its activation potently suppresses insulin secretion. SSTR5 activation also reduces secretion of the incretin hormones GIP and GLP-1. Pasireotide's lower SSTR2 affinity means glucagon suppression (an SSTR2-mediated alpha-cell effect) is relatively modest. The net effect is reduced insulin output without a compensating fall in glucagon — a pathophysiology distinct from octreotide's more balanced insulin/glucagon suppression — producing hyperglycemia in a majority of treated patients. Signaling biology also differs: pasireotide acts as a partial agonist at SSTR2 with an unusual pattern of receptor phosphorylation, internalization, and trafficking compared to octreotide, which may contribute to functional differences at this subtype despite nominal binding overlap.
Evidence Snapshot
Human Clinical Evidence
Strong for labeled indications. Two phase III Cushing's disease trials (subcutaneous and LAR) and two phase III acromegaly trials (C2305 head-to-head vs octreotide, PAOLA vs continued octreotide/lanreotide) anchor the approval package. NET and pancreatic-fistula data are phase II/III with positive but smaller-scale results.
Animal / Preclinical
Comprehensive. Broad SRIF-receptor pharmacology is well-characterized in rodent, primate, and canine studies.
Mechanistic Rationale
Very strong. Pasireotide's SSTR5-dominant binding profile directly explains both its therapeutic niche in Cushing's disease and its hyperglycemia signature through pancreatic beta-cell biology.
Research Gaps & Open Questions
What the current literature has not yet settled about Pasireotide:
- 01Predictors of response in Cushing's disease — pasireotide works better in some patients than others, with tumor SSTR5 expression and baseline cortisol burden partial predictors, but pre-treatment biomarkers that reliably identify responders are not standardized.
- 02Long-term cardiovascular outcomes of pasireotide-induced hyperglycemia — whether the diabetes risk translates into increased macrovascular events over 5–10 years of exposure remains under-characterized, particularly in acromegaly where pasireotide is often chosen over octreotide/lanreotide explicitly for efficacy despite this trade-off.
- 03Optimal glycemic-management algorithm — expert consensus favors DPP-4 inhibitors and GLP-1 agonists, but head-to-head trials comparing glycemic strategies in pasireotide-treated patients are limited.
- 04Durability of NET response — phase II/III NET data show activity in octreotide-refractory disease, but the relative positioning of pasireotide vs everolimus, sunitinib, and PRRT (Lutathera) in the modern sequencing algorithm is not fully resolved.
- 05Postoperative pancreatic fistula prophylaxis — the Allen et al. 2014 NEJM trial was positive at a single center, but subsequent multi-center studies and meta-analyses have been more heterogeneous, leaving optimal patient selection (dilated vs non-dilated duct, pancreaticoduodenectomy vs distal pancreatectomy) unresolved.
- 06Pregnancy safety — limited human pregnancy data; case reports and small case series exist, but formal pregnancy outcome data are insufficient for definitive guidance.
- 07Head-to-head comparison with medical adrenal-blocker options (osilodrostat, metyrapone, ketoconazole) in Cushing's disease — randomized comparative-effectiveness data between pituitary-directed pasireotide and steroidogenesis inhibitors remain limited, complicating drug-choice algorithms.
- 08Combination pasireotide + cabergoline or pasireotide + ketoconazole regimens in Cushing's disease have shown additive benefit in small studies but lack large-scale validation.
Forms & Administration
Two formulations. Signifor (immediate-release subcutaneous): 0.3 mg, 0.6 mg, or 0.9 mg SC twice daily, primarily for Cushing's disease. Signifor LAR (long-acting depot): 10, 20, 40, or 60 mg intramuscular gluteal injection every 4 weeks, approved for both Cushing's disease and acromegaly. LAR is administered by a healthcare provider. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Immediate-release subcutaneous pasireotide (Signifor) is dosed 0.3 mg, 0.6 mg, or 0.9 mg SC twice daily for Cushing's disease, with individual titration between those fixed dose levels. The long-acting depot (Signifor LAR) is dosed 10, 20, 40, or 60 mg intramuscularly every 4 weeks. Cushing's disease LAR dosing typically centers on 10–30 mg monthly; acromegaly LAR dosing centers on 40–60 mg monthly.
Frequency
Immediate-release SC: twice daily (morning and evening), rotated between injection sites. LAR depot: every 4 weeks by gluteal intramuscular injection, administered by a healthcare provider. Cushing's disease patients are typically initiated on SC pasireotide for tolerability assessment and dose-finding; those requiring long-term therapy may transition to LAR depot.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Pasireotide is chronic indefinite therapy for Cushing's disease, acromegaly, and NET symptom control — not a cyclable peptide in the wellness sense. Treatment continues as long as biochemical benefit is demonstrated and side effects remain manageable. For postoperative pancreatic fistula prevention, the duration in the Allen et al. trial was a short perioperative course of 7 days.
Protocol Notes
Hyperglycemia is the defining dosing consideration. Fasting glucose and HbA1c should be checked at baseline, and glucose monitoring should start within the first weeks of therapy. Expert consensus recommends DPP-4 inhibitors (sitagliptin, linagliptin) or GLP-1 receptor agonists as first-line glycemic management rather than metformin, because the pathophysiology is insulin-secretion-deficient rather than insulin-resistance-driven. Patients with pre-existing diabetes, poor baseline glycemic control, or other cardiometabolic risk factors have a steeper hyperglycemia trajectory on pasireotide and require tighter management. Baseline ECG is required before initiating pasireotide, with correction of any hypokalemia or hypomagnesemia first. QT-prolongation data from the phase I crossover study showed a modest mean ΔΔQTcI of roughly 13 ms at therapeutic 600 mcg doses; clinical use has produced few cases of QTcF >480 ms and no reported torsades de pointes, but the recommendation for ECG monitoring at initiation and during dose titration is retained in labeling. Gallbladder imaging (ultrasound) at baseline and periodically during chronic therapy is standard, mirroring octreotide practice. Liver enzymes should be checked at baseline and periodically — mild transaminase elevations occur in a minority of patients and may prompt dose adjustment. In Cushing's disease, overcorrection to hypocortisolism is possible, particularly during dose escalation or in patients with smaller cortisol-secreting burdens. Morning cortisol and symptoms of adrenal insufficiency (fatigue, hypotension, nausea) should be monitored. The LAR depot has a delayed-release profile similar to octreotide LAR — meaningful plasma concentrations develop over 1–2 weeks after first injection. In acromegaly, biochemical response assessment for LAR is typically at month 3 (after three monthly injections reach steady state). For patients switching from octreotide or lanreotide to pasireotide, dose equivalency is not 1:1 and is guided by clinical response rather than a conversion ratio; the C2305 and switch-study data provide the framework.
Pasireotide is FDA-approved for Cushing's disease (Signifor, Signifor LAR) and acromegaly second-line (Signifor LAR); use for neuroendocrine tumors and postoperative pancreatic fistula is off-label. It must be prescribed and monitored by an endocrinologist, surgical oncologist, or other specialist familiar with somatostatin-analog therapy and experienced in managing hyperglycemia in this population.
Timeline of Effects
Onset
Subcutaneous immediate-release pasireotide produces detectable plasma concentrations within 30 minutes and measurable cortisol suppression in Cushing's disease within days; in the registration trial, median urinary free cortisol had decreased by approximately 50% by month 2 of therapy. Hyperglycemia typically emerges within the first 1–2 weeks, which is why glucose monitoring should begin early. The LAR depot has a delayed-release profile: meaningful plasma concentrations develop over 1–2 weeks after first injection, and biochemical response is typically assessed after three monthly depot cycles (~month 3) when near steady-state is reached.
Peak Effect
Immediate-release SC peak plasma concentration is within approximately 30 minutes after dosing, with suppression effects persisting across the twice-daily interval. For LAR, steady-state plasma concentrations are reached by approximately month 3 (after three monthly IM injections), which is the standard assessment point for biochemical response in both Cushing's disease and acromegaly. The peak biochemical benefit in responders continues to accrue over 6–12 months as tumor burden stabilizes and the somatostatin-receptor-mediated effect consolidates.
After Discontinuation
Immediate-release SC pasireotide has a terminal plasma half-life of roughly 12 hours, with essentially complete clearance over 1–2 days after the last dose. After LAR discontinuation, plasma concentrations decline over 4–6 weeks as the microsphere depot exhausts. Underlying disease activity (hypercortisolism in Cushing's disease, GH/IGF-1 excess in acromegaly) returns to pre-treatment levels in parallel — there is no disease-modifying residual benefit, and clinical deterioration can be rapid in Cushing's disease patients with high pre-treatment cortisol burdens. Hyperglycemia induced by pasireotide generally reverses over weeks after discontinuation, though patients with emergent frank diabetes may retain elevated glucose requiring ongoing glycemic therapy.
Monitoring & Measurement
Bloodwork & Labs
- •Fasting plasma glucose and HbA1c — baseline, at 4 weeks, then every 3 months; primary safety monitoring
- •Urinary free cortisol (Cushing's disease) — baseline, monthly during titration, then quarterly
- •Late-night salivary cortisol (Cushing's disease) — adjunct to UFC for diurnal variation assessment
- •Serum IGF-1 (acromegaly) — baseline, then every 3 months; primary biochemical endpoint
- •Random GH or GH during oral glucose tolerance test (acromegaly) — adjunct to IGF-1 for biochemical confirmation
- •Liver function tests (ALT, AST, bilirubin) — baseline, then periodically
- •Serum electrolytes with emphasis on potassium and magnesium — baseline and periodically (QT-related)
- •Thyroid function tests — TSH suppression can occur and warrants monitoring
Functional & Performance Tests
- •ECG — baseline before initiation, then periodically (QT interval monitoring)
- •Gallbladder ultrasound — baseline and periodically (annually or with new symptoms)
- •Pituitary MRI (Cushing's disease, acromegaly) — baseline and annually to monitor tumor volume
When to Test
Baseline before initiation; weekly glucose checks during the first month (particularly after dose changes); HbA1c and comprehensive biomarkers at 4 weeks, then every 3 months while on chronic therapy. Pituitary MRI and gallbladder ultrasound annually once stable.
Interpretation & Notes
The hyperglycemia signal is the dominant monitoring story — fasting glucose may be normal while postprandial glucose is markedly elevated, so HbA1c and periodic postprandial checks matter more than isolated fasting values. In Cushing's disease, 'response' means urinary free cortisol within normal range plus clinical improvement (blood pressure, weight, metabolic profile, quality of life); the phase III registration trials showed approximately half of responders achieved biochemical normalization by month 2. In acromegaly, 'response' means IGF-1 within age-adjusted normal range with concurrent random GH <1 mcg/L; biochemical control rates in real-world pooled data run roughly 30–60% depending on line of therapy and pre-treatment status. All monitoring is specialist-coordinated; this is not a peptide where self-monitoring is appropriate.
Common Questions
Who Pasireotide Is NOT For
- •Known hypersensitivity to pasireotide or to any formulation excipient.
- •Uncontrolled pre-existing diabetes mellitus — hyperglycemia is likely to worsen substantially; glycemic status should be optimized before initiation.
- •Baseline QTc prolongation, congenital long QT syndrome, or clinically significant cardiac arrhythmias — pasireotide produces modest QTc prolongation that may be clinically problematic in susceptible patients.
- •Uncorrected hypokalemia or hypomagnesemia — both must be corrected before initiation to minimize QT-related risk.
- •Significant hepatic impairment (Child-Pugh B or C) — dose adjustment or avoidance is warranted given altered exposure.
- •Pre-existing significant gallstone disease or recurrent biliary symptoms — relative contraindication; gallbladder motility reduction aggravates stone formation risk.
- •Concurrent bradycardia or on drugs known to cause significant bradycardia without appropriate monitoring — pasireotide can induce sinus bradycardia.
- •Pregnancy — not recommended unless benefit outweighs risk; somatostatin analogs cross the placenta and can affect fetal development.
- •Breastfeeding — limited data on transfer into breast milk; use is individualized with specialist input.
Drug & Supplement Interactions
Pasireotide has several clinically meaningful drug interactions driven by its pharmacodynamic effects on glucose, heart rate, and QT interval, plus modest pharmacokinetic interactions. Glucose-regulating medications: pasireotide's hyperglycemia signal makes concurrent antidiabetic therapy a central consideration. DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin) and GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) are first-line for pasireotide-associated hyperglycemia per expert consensus, because the underlying pathophysiology is SSTR5-mediated suppression of insulin and incretin secretion rather than insulin resistance — metformin is less effective than in other diabetic contexts. Insulin and sulfonylureas can be used when needed but require close titration. QT-prolonging drugs: class Ia and class III antiarrhythmics, several antipsychotics (haloperidol, thioridazine, ziprasidone), macrolide antibiotics (erythromycin, clarithromycin), fluoroquinolones, some antiemetics (ondansetron at higher doses, domperidone), and methadone have additive QT-prolongation risk with pasireotide. Co-administration should be avoided or monitored with ECGs and electrolyte surveillance. Bradycardia-inducing drugs: beta blockers, non-dihydropyridine calcium-channel blockers (verapamil, diltiazem), and digoxin have additive bradycardia risk. Baseline and periodic heart rate assessment is appropriate. Cyclosporine: as with octreotide, pasireotide can reduce cyclosporine absorption, potentially lowering immunosuppressant exposure and demanding drug-level monitoring in transplant patients. Drugs metabolized through biliary excretion or affected by gallbladder motility may have altered disposition with chronic pasireotide therapy; clinical significance is generally small but warrants awareness. Warfarin and other narrow-therapeutic-index agents: altered hepatic metabolism through GH suppression may slightly shift exposure; INR should be followed more closely during initiation and dose changes. Unlike MK-677 or some small-molecule endocrine drugs, pasireotide is not a significant CYP450 substrate, inducer, or inhibitor in human studies, so most pharmacokinetic interactions are modest. Pharmacodynamic interactions (glucose, cardiac conduction, QT) are the dominant clinical story.
Safety Profile
Common Side Effects
Cautions
- • Baseline and serial HbA1c plus fasting glucose monitoring is mandatory — hyperglycemia often emerges within weeks
- • Baseline ECG plus electrolyte correction (potassium, magnesium) before initiation
- • Baseline and periodic gallbladder imaging during chronic therapy
- • Liver function monitoring; use with caution in moderate hepatic impairment
- • Pituitary hormone axis monitoring in Cushing's disease (risk of overcorrection to hypocortisolism)
- • Not for pregnancy unless benefit outweighs risk; crosses placenta
What We Don't Know
Pasireotide has a well-defined phase III safety profile from Cushing's disease and acromegaly registration programs but a narrower long-term real-world dataset than octreotide. The dominant safety story is hyperglycemia and its long-term cardiovascular and microvascular consequences — still accumulating in registry data.
Legal Status
United States
Pasireotide is FDA-approved. Signifor (immediate-release subcutaneous) was approved in December 2012 for patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. Signifor LAR (long-acting release IM depot) was approved in December 2014 for acromegaly patients who have had an inadequate response to surgery and/or for whom surgery is not an option, and subsequently for Cushing's disease. It is a prescription-only medication, not a controlled substance, and is distributed through specialty pharmacies. There is no generic equivalent; the molecule remains under Novartis exclusivity-derived pricing at the time of writing.
International
Approved by the EMA for Cushing's disease (April 2012) and by regulators in the UK, Canada, Japan, Australia, and most major markets. The indication profile is generally aligned with the FDA label: Cushing's disease after failed or contraindicated surgery, and acromegaly inadequately controlled on first-generation somatostatin analogs.
Sports & Competition
Pasireotide is not specifically named on the WADA Prohibited List. Because it suppresses growth hormone secretion rather than elevating it, performance-enhancing abuse potential is negligible, and it has not been a notable anti-doping concern. Athletes with diagnosed acromegaly or Cushing's disease using pasireotide under appropriate medical documentation should coordinate with anti-doping authorities for therapeutic use exemption documentation if required.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Pasireotide is just a stronger version of octreotide.
Reality
Pasireotide is not 'stronger' — it has a fundamentally different receptor-binding profile. It has roughly 40-fold higher affinity for SSTR5 than octreotide, but modestly lower SSTR2 affinity. This is why it works in Cushing's disease (SSTR5-driven) where octreotide does not, and why it causes hyperglycemia more frequently than octreotide (SSTR5 is highly expressed on pancreatic beta cells). The two drugs occupy different clinical niches, not different potencies.
Myth
The hyperglycemia from pasireotide means it should not be used in patients with diabetes.
Reality
Pre-existing diabetes is a relative consideration, not an absolute contraindication. Pasireotide is routinely used in patients with Cushing's-disease-associated diabetes (where hypercortisolism itself drives hyperglycemia and may improve with cortisol control) and in acromegaly patients with GH-driven glucose intolerance. What matters is proactive glycemic management with the right agents (DPP-4 inhibitors, GLP-1 agonists) rather than metformin, and tight monitoring. Uncontrolled baseline diabetes should be stabilized first, but well-managed diabetes does not preclude use.
Myth
Pasireotide is first-line medical therapy for acromegaly.
Reality
No — it is FDA-approved as second-line for acromegaly, for patients inadequately controlled on, or intolerant of, octreotide or lanreotide. The PAOLA and C2305 trials established superior biochemical control versus first-generation somatostatin analogs, but the hyperglycemia trade-off means first-generation analogs remain first-line after surgery. Pasireotide's first-line niche is Cushing's disease, not acromegaly.
Myth
Because pasireotide suppresses GH, bodybuilders could use it to manage HGH-related side effects or insulin resistance.
Reality
This is dangerous off-label thinking. Pasireotide causes new-onset or worsened diabetes in 60–75% of treated patients — it would aggravate, not mitigate, HGH-related insulin resistance. It also produces gallstones, QT prolongation, and bradycardia with chronic use. Beyond the side-effect profile, there is no clinical evidence base for any wellness, performance, or aesthetic use. Like octreotide, it is a specialist-prescribed drug for serious endocrine and oncology indications.
Myth
Cortisol normalization on pasireotide means the pituitary tumor is being controlled.
Reality
Biochemical control (normal urinary free cortisol) and tumor control are related but not identical endpoints in Cushing's disease. Pasireotide reliably suppresses ACTH secretion and lowers cortisol in responders, and modest pituitary-tumor-volume reductions have been observed in some patients — but tumor shrinkage is variable and not guaranteed. Cushing's disease management requires both biochemical assessment (urinary free cortisol, late-night salivary cortisol, serum cortisol) and serial pituitary MRI to monitor tumor behavior.
Published Research
31 studiesImpact of pasireotide on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis
Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis
Efficacy and safety of pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis
Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement
Incretin Response to Mixed Meal Challenge in Active Cushing's Disease and after Pasireotide Therapy
Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study
Meta-Analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula
Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study
Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial
Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
Pasireotide in Acromegaly: A Review
Clinical use of pasireotide for Cushing's disease in adults
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
PAOLA trial (Gadelha et al., Lancet Diabetes Endocrinol 2014): phase III study in patients with acromegaly inadequately controlled on first-generation somatostatin analogs. Pasireotide 40 and 60 mg LAR produced biochemical control in 15–20% of patients vs 0% with continued octreotide/lanreotide — the evidentiary basis for second-line FDA approval in acromegaly.
Pasireotide for postoperative pancreatic fistula
Allen et al., NEJM 2014: 300 patients undergoing pancreatic resection randomized to perioperative pasireotide 900 mcg SC BID vs placebo. Clinically significant fistula/leak/abscess reduced from 21% to 9% (RR 0.44). Single-center positive trial that prompted widespread off-label adoption, though subsequent multi-center studies have been more mixed.
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study
C2305 trial (Colao et al., JCEM 2014): 358 medically naive acromegaly patients randomized to pasireotide LAR 40 mg or octreotide LAR 20 mg every 28 days. Pasireotide demonstrated superior biochemical control (31.3% vs 19.2%, P=0.007), establishing it as a first-line alternative when warranted.
Effects of Subcutaneous Pasireotide on Cardiac Repolarization in Healthy Volunteers: a Single-Center, Phase I, Randomized, Four-Way Crossover Study
Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers
Henry et al., JCEM 2013: mechanistic healthy-volunteer study demonstrating that pasireotide-induced hyperglycemia is driven by suppressed insulin and incretin (GIP/GLP-1) secretion with preserved hepatic/peripheral insulin sensitivity — the mechanistic basis for preferring DPP-4 inhibitors and GLP-1 agonists over metformin as first-line management.
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
A 12-month phase 3 study of pasireotide in Cushing's disease
Registration trial (Colao et al., NEJM 2012) establishing subcutaneous pasireotide efficacy in Cushing's disease: 162 patients randomized to 600 or 900 mcg SC BID, with urinary free cortisol normalization as primary endpoint. This is the seminal paper that led to FDA approval.
Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation
Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro
Pasireotide (SOM230): development, mechanism of action and potential applications
SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
Bruns et al., Eur J Endocrinol 2002: the foundational receptor-pharmacology paper defining pasireotide's pan-somatostatin-receptor profile with 30–40-fold higher affinity for SSTR1 and SSTR5 than octreotide. Underpins every subsequent clinical rationale for the molecule.
Quick Facts
- Class
- Pan-Somatostatin Analog / SSTR1/2/3/5 Agonist
- Evidence
- Strong
- Safety
- Moderate Data
- Updated
- Apr 2026
- Citations
- 31PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.